Pfizer CentreOne
Pfizer CentreOne is the contract manufacturing arm of Pfizer Inc., offering commercial-scale oral solid dose, sterile injectable, antibody-drug conjugate, and microbial fermentation services to pharmaceutical and biotechnology companies across 150+ countries.
- Company typePrivate
- Founded1984
- HeadquartersNew York, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Pfizer CentreOne does
Pfizer CentreOne is the contract manufacturing organization (CMO) arm of Pfizer Inc., providing commercial-scale pharmaceutical manufacturing services to enterprise pharmaceutical and biotechnology clients. Founded circa 1984, the business operates 11+ manufacturing sites across the United States (McPherson, Pearl River, North Creek/Bothell, Sanford) and Europe (Ascoli Piceno, Freiburg, Newbridge, Algete, Puurs, Strängnäs, Zagreb), spanning oral solid dose, sterile injectables, antibody-drug conjugates (ADCs), and microbial fermentation. Its technology stack includes aseptic fill-finish, lyophilization, pre-filled syringe manufacturing, high-containment processing (OEB 1-5), single-use ADC conjugation, and mammalian cell culture, supported by a proprietary Integrated Manufacturing Excellence (IMEx) operating system and a structured seven-phase tech transfer methodology.
Pfizer CentreOne generates revenue through fee-for-service, multi-year contract manufacturing agreements with three primary customer segments: large pharmaceutical companies, biotechnology companies (with a particular focus on ADCs and complex biologics), and generic pharmaceutical manufacturers. Pricing is quote-based and project-specific, with no public price list. The go-to-motion is enterprise field sales — dedicated business development leads, portfolio leads, and account management — supplemented by thought leadership content (whitepapers, webinars, podcasts, case studies) and presence at BIO, CPHI, Contract Pharma, and BIO-Europe. The franchise is differentiated by regulatory coverage across 150+ countries, a 40+ year CMO track record, 8 consecutive years of CDMO Leadership Awards (2017–2024), and the heritage of producing the world's first commercially approved ADC (Mylotarg). Pfizer CentreOne does not disclose standalone revenue, operates without separate external funding, and is wholly owned by Pfizer Inc. (NYSE: PFE).
Pfizer CentreOne firmographics
Firmographics- Name
- Pfizer CentreOne
- Legal name
- Pfizer Inc.
- Website
- https://pfizercentreone.com
- Company type
- Private
- Founded year
- 1984
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Pfizer CentreOne is the contract manufacturing arm of Pfizer Inc., offering commercial-scale oral solid dose, sterile injectable, antibody-drug conjugate, and microbial fermentation services to pharmaceutical and biotechnology companies across 150+ countries.
- Ownership category
- akta.pro rank
Pfizer CentreOne industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
- akta.pro secondary industries
- GMP Manufacturing Support Services (QA/QMS, validation, documentation) (HLAAAKAH), Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP) (HLAGAGAG), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where Pfizer CentreOne is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices11 records
Markets served
Pfizer CentreOne business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Contract Manufacturing Services: Pfizer CentreOne generates revenue through fee-for-service contract manufacturing agreements with pharmaceutical and biotech companies. Services include manufacturing of oral solid dose, sterile injectables, antibody-drug conjugates, and biologic drug products. Revenue is project-based with pricing negotiated per contract, typically covering development, manufacturing, fill-finish, and regulatory support services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom contract manufacturing services with project-based pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels10 records
Pfizer CentreOne product offering
Product offeringCore offering
Pfizer CentreOne is a contract manufacturing organization (CMO) that provides pharmaceutical and biotech companies with commercial-scale manufacturing services for oral solid dose (OSD) drugs, sterile injectables, antibody-drug conjugates (ADCs), and microbial fermentation products. The services span late-stage clinical through commercial production, supported by technology transfer expertise, regulatory support across 150+ countries, and IP protection frameworks, all delivered through Pfizer's global manufacturing network.
Product overview
Pfizer CentreOne is an award-winning Contract Manufacturing Organization (CMO) offering a comprehensive portfolio of pharmaceutical manufacturing services powered by Pfizer's global network. The company provides three core manufacturing service lines—Oral Solid Dose (OSD), Sterile Injectables, and Antibody-Drug Conjugates (ADC)—supported by dedicated manufacturing networks across multiple global sites. The product portfolio also includes Microbial Fermentation, Tech Transfer Services, Regulatory Support, and IP Protection. These services are integrated under Pfizer CentreOne's unified offering, where manufacturing capabilities span from late-stage clinical through commercialization, leveraging shared regulatory expertise across 150+ countries and Pfizer's infrastructure of over $1B annual manufacturing investment.
Differentiator
Problem solved
Functional benefit
Products and services
- Oral Solid Dose (OSD) Manufacturing Services Contract manufacturing of oral solid dose drug products including pellets, tablets, and capsules, supporting immediate-release and modified-release profiles (prolonged, delayed, and multiphase). Capabilities span dry granulation, wet granulation, extrusion/spheronization, compression, encapsulation, coating, and packaging, with high-containment facilities handling OEB 1-5 highly potent compounds. Built for pharmaceutical and biotech customers requiring commercial-scale OSD supply across global markets.
- Sterile Injectables Manufacturing Services Contract manufacturing of sterile injectable drug products including liquid and lyophilized formulations, aseptic fill-finish, and terminal sterilization. Container closure options include glass vials (2-100mL), pre-filled syringes (1-5mL), cartridges, and ampoules, with advanced aseptic filling using isolator and RABS technology. Built for pharmaceutical and biotech customers needing commercial-scale sterile injectable capacity across biologics, small molecules, combination products, and vaccines.
- Antibody-Drug Conjugate (ADC) Manufacturing Services End-to-end ADC manufacturing services from mammalian cell culture through conjugation, purification, formulation, and fill-finish, supported by over two decades of experience and purpose-built facilities at Pearl River, NY and North Creek (Bothell), WA. The Pearl River site provides ~24,000 sq.ft for highly potent and cytotoxic ADC processing, while North Creek offers 51,000 sq.ft with advanced single-use technologies for clinical and commercial cGMP manufacturing. Designed for biotech and pharma partners developing novel antibody-drug conjugates.
- Microbial Fermentation Services Contract microbial fermentation for vaccines, growth hormones, and biologic drug substances, with advanced harvest and purification technologies. The Strängnäs site has 70+ years of manufacturing experience supported by 370+ Pfizer experts, and the Zagreb site has 13+ years of biologics drug substance and drug product manufacturing experience on an 11-acre campus. Built for pharmaceutical and biotech customers requiring microbial-derived biologics.
- Pharmaceutical Tech Transfer Services Technology transfer services supporting seamless transitions from clinical to commercial manufacturing, using a structured, unified approach covering geographic footprint, technology, personnel, regulatory compliance, collaboration, and quality. Leverages digital infrastructure, deep regulatory expertise across 150+ countries, and coordinated global teams. Built for pharmaceutical and biotech partners scaling manufacturing programs.
- Regulatory Support and IP Protection Services End-to-end regulatory affairs support for submissions across 150+ countries, backed by a regulatory team with 80+ years of combined experience and inspection credentials at FDA, EMA, PMDA, MHRA, Health Canada, ANVISA, NMPA, TGA, and other agencies. IP protection is delivered through Pfizer's security protocols and frameworks, providing peace of mind, reliability, and uncompromising quality for partners' outsourced manufacturing programs.
Quantifiable outcome
- Over 90% on-time, in-full (OTIF) delivery with no issues on audit
- +2 more outcomes
Companies that use Pfizer CentreOne
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Pfizer CentreOne technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Pfizer CentreOne partnerships and signals
Strategic signalScale indicators13 records
Recent moves5 records
Expansion highlights5 records
Pfizer CentreOne competitors and assessment
Company assessmentDirect peers
- Lonza Group: Lonza is one of the world's largest contract development and manufacturing organizations, offering biologics, small molecules, and cell & gene therapy manufacturing — directly competing with Pfizer CentreOne across multiple modalities including ADCs and sterile injectables.
- Catalent: Catalent is a major global CDMO providing oral dose, sterile injectable, and biologic drug product manufacturing services to pharma and biotech customers — a direct competitor in OSD, sterile injectables, and tech transfer services.
- Samsung Biologics: Samsung Biologics is a leading contract manufacturer of biopharmaceuticals offering mammalian cell culture, fill-finish, and aseptic manufacturing services — competing directly for biologics and ADC contract manufacturing work.
- WuXi Biologics: WuXi Biologics provides end-to-end biologics contract manufacturing including cell line development, drug substance, and drug product services — a direct competitor for mammalian-based biologics and ADC manufacturing partnerships.
- Siegfried Holding: Siegfried is a Swiss-based CDMO specializing in oral solid dose and sterile injectable manufacturing for the pharmaceutical industry — directly comparable in OSD and API manufacturing services.
- AGC Biologics: AGC Biologics is a global biopharmaceutical contract manufacturer offering mammalian cell culture, microbial fermentation, and fill-finish services — directly competing for biologics and vaccine manufacturing programs.
- Recipharm: Recipharm is a European-based contract development and manufacturing organization focused on sterile injectables, oral solids, and inhalation products — directly comparable in OSD and sterile injectable contract manufacturing services.
Broad incumbents
- Boehringer Ingelheim BioXcellence: Boehringer Ingelheim's BioXcellence is a large biopharmaceutical contract manufacturing business offering mammalian and microbial biologics production — competing for ADC and biologics manufacturing opportunities with deeper parent-company R&D resources.
- FUJIFILM Diosynth Biotechnologies: FUJIFILM Diosynth is a major contract manufacturer of biologics including vaccines, monoclonal antibodies, and ADCs — a broad incumbent competing for the same biotech and pharma manufacturing partnerships.
- Thermo Fisher Scientific (Patheon): Thermo Fisher's pharma services business (including Patheon) provides comprehensive contract manufacturing, development, and clinical trial services — a broad incumbent offering OSD, sterile injectables, and biologics at scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Pfizer CentreOne social profiles
Digital presencePfizer CentreOne compliance and trust
Trust signalCompliance11 records
Pfizer CentreOne financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pfizer CentreOne leadership team
Management profileNumber of profiles
Profiles17 records
Pfizer CentreOne funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pfizer CentreOne M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pfizer CentreOne
What does Pfizer CentreOne do?
Pfizer CentreOne is a contract manufacturing organization (CMO) that provides pharmaceutical and biotech companies with commercial-scale manufacturing services for oral solid dose (OSD) drugs, sterile injectables, antibody-drug conjugates (ADCs), and microbial fermentation products. The services span late-stage clinical through commercial production, supported by technology transfer expertise, regulatory support across 150+ countries, and IP protection frameworks, all delivered through Pfizer's global manufacturing network.
Is Pfizer CentreOne a public or private company?
Pfizer CentreOne is a private company. It is classified as corporate owned and is currently operating.
When was Pfizer CentreOne founded?
Pfizer CentreOne was founded in 1984. It employs 101 to 250 people.
Where is Pfizer CentreOne based?
Pfizer CentreOne is headquartered in New York, United States, in the North America region.
How does Pfizer CentreOne make money?
One revenue line is on record: contract Manufacturing Services.
Who are Pfizer CentreOne's main competitors?
Direct peers on record are Lonza Group, Catalent, Samsung Biologics, WuXi Biologics, Siegfried Holding, AGC Biologics and Recipharm. Broad incumbents are Boehringer Ingelheim BioXcellence, FUJIFILM Diosynth Biotechnologies and Thermo Fisher Scientific (Patheon).
Does Pfizer CentreOne have an API?
No public API is recorded for Pfizer CentreOne.
What industry is Pfizer CentreOne in?
Pfizer CentreOne's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO), with a secondary code of HLAAAKAH, GMP Manufacturing Support Services (QA/QMS, validation, documentation). Its NAICS code is 325412 and its SIC code is 2834.